脓毒性休克中的血管加压药与正性肌力药支持:一项循证综述
Vasopressor and inotropic support in septic shock: an evidence-based review.
作者信息
Beale Richard J, Hollenberg Steven M, Vincent Jean-Louis, Parrillo Joseph E
机构信息
Guy's and St. Thomas' NHS Foundation Trust, London, UK.
出版信息
Crit Care Med. 2004 Nov;32(11 Suppl):S455-65. doi: 10.1097/01.ccm.0000142909.86238.b1.
OBJECTIVE
In 2003, critical care and infectious disease experts representing 11 international organizations developed management guidelines for vasopressor and inotropic support in septic shock that would be of practical use for the bedside clinician, under the auspices of the Surviving Sepsis Campaign, an international effort to increase awareness and to improve outcome in severe sepsis.
DESIGN
The process included a modified Delphi method, a consensus conference, several subsequent smaller meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee.
METHODS
The modified Delphi methodology used for grading recommendations built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations to contrast adult and pediatric management are in the article by Parker et al. on p. S591.
CONCLUSION
An arterial catheter should be placed as soon as possible in patients with septic shock. Vasopressors are indicated to maintain mean arterial pressure of <65 mm Hg, both during and following adequate fluid resuscitation. Norepinephrine or dopamine are the vasopressors of choice in the treatment of septic shock. Norepinephrine may be combined with dobutamine when cardiac output is being measured. Epinephrine, phenylephrine, and vasopressin are not recommended as first-line agents in the treatment of septic shock. Vasopressin may be considered for salvage therapy. Low-dose dopamine is not recommended for the purpose of renal protection. Dobutamine is recommended as the agent of choice to increase cardiac output but should not be used for the purpose of increasing cardiac output above physiologic levels.
目的
2003年,代表11个国际组织的重症监护和传染病专家在“拯救脓毒症运动”的支持下制定了脓毒性休克血管活性药物和正性肌力药物支持的管理指南,该指南对床边临床医生具有实际应用价值。“拯救脓毒症运动”是一项提高对严重脓毒症的认识并改善其预后的国际行动。
设计
该过程包括改良德尔菲法、共识会议、随后几个小组和关键人物的小型会议、电话会议以及小组之间和整个委员会的电子讨论。
方法
用于分级推荐的改良德尔菲法基于国际脓毒症论坛2001年赞助的一份出版物。我们对文献进行了系统评价,并根据五个级别进行分级,以创建从A到E的推荐等级,A为最高等级。帕克等人在第S591页的文章中讨论了对比成人和儿童管理的儿科注意事项。
结论
脓毒性休克患者应尽快放置动脉导管。在充分液体复苏期间及之后,均需使用血管活性药物维持平均动脉压<65 mmHg。去甲肾上腺素或多巴胺是治疗脓毒性休克的首选血管活性药物。在测量心输出量时,去甲肾上腺素可与多巴酚丁胺联合使用。不推荐将肾上腺素、去氧肾上腺素和血管加压素作为脓毒性休克治疗的一线药物。血管加压素可考虑用于挽救治疗。不推荐使用小剂量多巴胺进行肾脏保护。推荐多巴酚丁胺作为增加心输出量的首选药物,但不应将其用于将心输出量增加至生理水平以上的目的。